Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine‐induced weight gain

Olanzapine is an atypical antipsychotic known to cause considerable weight gain. The cannabinoid type 1 receptor has been reported to be involved in energy balance control, appetite stimulation, and increases in body weight.

[1]  M. Maj,et al.  Endocannabinoid Pro129Thr FAAH Functional Polymorphism But Not 1359G/A CNR1 Polymorphism Is Associated With Antipsychotic-Induced Weight Gain , 2010, Journal of clinical psychopharmacology.

[2]  Young-Min Park,et al.  Lack of Association between Glutathione S-Transferase-M1, -T1, and -P1 Polymorphisms and Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients , 2010, Psychiatry investigation.

[3]  J. Lieberman,et al.  A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia , 2010, Neuropsychopharmacology.

[4]  Young-Min Park,et al.  G-protein β3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients , 2009, Psychiatry investigation.

[5]  D. Selley,et al.  Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats , 2008, Neuropharmacology.

[6]  Xu-Feng Huang,et al.  The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. , 2008, The international journal of neuropsychopharmacology.

[7]  T. Hansen,et al.  Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. , 2008, Human molecular genetics.

[8]  Jung-Eun Choi,et al.  Lack of association between the −759C/T polymorphism of the 5‐HT2C receptor gene and olanzapine‐induced weight gain among Korean schizophrenic patients , 2008, Journal of clinical pharmacy and therapeutics.

[9]  Young-Min Park,et al.  Possible association between the −2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  H Remschmidt,et al.  No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation , 2007, The Pharmacogenomics Journal.

[11]  D. Tregouet,et al.  Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. , 2007, The Journal of clinical endocrinology and metabolism.

[12]  T. Meitinger,et al.  No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. , 2007, Molecular genetics and metabolism.

[13]  D. Rader,et al.  Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. , 2007, Trends in cardiovascular medicine.

[14]  Giacomo Mancini,et al.  Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. , 2006, Current opinion in pharmacology.

[15]  Young-Min Park,et al.  Weight gain associated with the α2a‐adrenergic receptor −1291 C/G polymorphism and olanzapine treatment , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[16]  D. Osei-Hyiaman,et al.  The role of the endocannabinoid system in the control of energy homeostasis , 2006, International Journal of Obesity.

[17]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[18]  J. Orr,et al.  Dietary influences on peripheral hormones regulating energy intake: potential applications for weight management. , 2005, Journal of the American Dietetic Association.

[19]  Patrice D Cani,et al.  Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide , 2004, British Journal of Nutrition.

[20]  N. Rüsch,et al.  Understanding adherence to neuroleptic treatment in schizophreniaı́ , 2004, Psychiatry Research.

[21]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[22]  N. Rüsch,et al.  Understanding adherence to neuroleptic treatment in schizophreniaí. , 2004, Psychiatry research.

[23]  R. Ganguli,et al.  Body mass index and quality of life in community-dwelling patients with schizophrenia , 2003, Schizophrenia Research.

[24]  D. Allison,et al.  The impact of weight gain on quality of life among persons with schizophrenia. , 2003, Psychiatric services.

[25]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  H. Nasrallah.  A review of the effect of atypical antipsychotics on weight , 2003, Psychoneuroendocrinology.

[27]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .

[28]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[29]  S. Zorn,et al.  The pharmacology of weight gain with antipsychotics. , 2001, The Journal of clinical psychiatry.

[30]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[31]  D. Taylor,et al.  Atypical antipsychotics and weightgain — a systematic review , 2000, Acta psychiatrica Scandinavica.

[32]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[33]  K. Müller-Vahl,et al.  A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. , 1999, Molecular and cellular probes.

[34]  T. Baptista.  Body weight gain induced by antipsychotic drugs: mechanisms and management , 1999, Acta psychiatrica Scandinavica.

[35]  D. Perkins.  Adherence to antipsychotic medications. , 1999, The Journal of clinical psychiatry.

[36]  R. Tandon,et al.  New atypical antipsychotic medications. , 1998, Journal of psychiatric research.

[37]  E. Gershon,et al.  Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. , 1997, Genomics.